Medistim

Regulatory Filings • Jun 30, 2016

Medistim's technology has achieved reimbursement in Japan

Medistim's technology has achieved reimbursement in Japan

(Oslo, 30 June 2016) Medistim ASA (OSE: MEDI), a

Norwegian company that develops and commercializes medical

medical equipment for use in cardiac, vascular and

transplant surgery, announces that reimbursement for the

the use of their technology is achieved in Japan.

About 20,000 coronary bypass surgery procedures are performed

performed annually in Japan, and more than 80% of these

these procedures are guided and controlled by the use of

of blood flow measurement and intraoperative ultrasound

ultrasound imaging technology from Medistim. This

makes Japan the most developed country in the world in

terms of adopting and routinely applying quality assessment

assessment and surgical guidance to improve CABG surgery

surgery.

Valid from 1st April 2016, the Ministry of Health,

Labour and Welfare in Japan approved a reimbursement of

of YEN 25,000 [EUR 225] when blood flow of the graft is

is controlled, using either transit time flow measurement

measurement or high-resolution epicardial ultrasonography

ultrasonography intraoperatively.

"This is a great milestone in Medistim's history" says

Kari E. Krogstad, CEO of Medistim ASA. "Achieving

reimbursement for the use of our technology after almost

almost two decades of developing routine use in Japan

is a great encouragement and affirmation of the value that

that is put on the clinical value of the technology. Hopefully

Hopefully, this could lead to more countries acknowledging

acknowledging the value of reimbursing the quality assessment

assessment and guidance aspects of CABG and other vascular

vascular surgery. The reimbursement achieved in Japan

is a result of the joint efforts of the industry and leading

leading surgeons, in particular Professor Hirokuni Arai

Arai, who has contributed strongly to the clinical acceptance

acceptance of the combined technology for ultrasonic surgical

surgical guidance and quality assessment during CABG surgery

surgery."

For more information, contact:

President & CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com

About Medistim

Medistim was established in 1984, and has a track record

record of profitable growth over the past >10 years.

The company is a pioneer within its segment, and continues

continues to invest in new product development. Medistim

Medistim has wholly owned subsidiaries with sales organizations

organizations in the US, Germany, Denmark, UK and

Norway, in addition to the around 50 distributors in

Europe, Asia, Middle East, Africa and South America.

For more information, visit the Medistim home page: w

www.Medistim.com